1. Home
  2. MATH vs CUE Comparison

MATH vs CUE Comparison

Compare MATH & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MATH
  • CUE
  • Stock Information
  • Founded
  • MATH 2015
  • CUE 2014
  • Country
  • MATH Hong Kong
  • CUE United States
  • Employees
  • MATH N/A
  • CUE N/A
  • Industry
  • MATH Finance/Investors Services
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MATH Finance
  • CUE Health Care
  • Exchange
  • MATH Nasdaq
  • CUE Nasdaq
  • Market Cap
  • MATH 64.9M
  • CUE 60.6M
  • IPO Year
  • MATH N/A
  • CUE 2018
  • Fundamental
  • Price
  • MATH $1.70
  • CUE $0.91
  • Analyst Decision
  • MATH
  • CUE Strong Buy
  • Analyst Count
  • MATH 0
  • CUE 4
  • Target Price
  • MATH N/A
  • CUE $4.75
  • AVG Volume (30 Days)
  • MATH 105.6K
  • CUE 147.0K
  • Earning Date
  • MATH 10-31-2024
  • CUE 05-08-2025
  • Dividend Yield
  • MATH N/A
  • CUE N/A
  • EPS Growth
  • MATH N/A
  • CUE N/A
  • EPS
  • MATH 0.17
  • CUE N/A
  • Revenue
  • MATH $31,399,049.00
  • CUE $9,532,000.00
  • Revenue This Year
  • MATH N/A
  • CUE $73.11
  • Revenue Next Year
  • MATH N/A
  • CUE $11.02
  • P/E Ratio
  • MATH $10.35
  • CUE N/A
  • Revenue Growth
  • MATH 291.58
  • CUE 149.53
  • 52 Week Low
  • MATH $0.80
  • CUE $0.45
  • 52 Week High
  • MATH $2.78
  • CUE $2.26
  • Technical
  • Relative Strength Index (RSI)
  • MATH 45.52
  • CUE 32.51
  • Support Level
  • MATH $1.70
  • CUE $0.95
  • Resistance Level
  • MATH $2.10
  • CUE $1.05
  • Average True Range (ATR)
  • MATH 0.14
  • CUE 0.08
  • MACD
  • MATH -0.02
  • CUE 0.00
  • Stochastic Oscillator
  • MATH 7.50
  • CUE 19.62

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: